Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera

Podobne zapisy

• Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi(®))
  od: Shanmugam, Victoria K., i wsp.
  Wydane: (2013)
• Ruxolitinib for the Treatment of Patients With Polycythemia Vera
  od: Kiladjian, Jean-Jacques, i wsp.
  Wydane: (2015)
• Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
  od: Raedler, Lisa
  Wydane: (2015)
• Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
  od: Raedler, Lisa A.
  Wydane: (2015)
• Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
  od: Raedler, Lisa A.
  Wydane: (2015)